Segment Information

9 Months Ended

Sep. 30, 2016

Segment Reporting [Abstract]

Segment Information

SEGMENT INFORMATION

We have one operating segment, which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Therefore, our results of operations are reported on a consolidated basis consistent with internal management reporting reviewed by our chief operating decision maker, our chief executive officer. Total product sales on an individual product basis are summarized in the following table (in millions):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2016		2015		2016		2015
Antiviral products:
Harvoni	$	1,860	$	3,332	$	7,441	$	10,519
Truvada	858		903		2,698		2,523
Sovaldi	825		1,466		3,460		3,729
Atripla	650		818		1,998		2,334
Epclusa	640		—		704		—
Stribild	621		511		1,527		1,314
Genvoya	461		—		921		—
Complera/Eviplera	411		360		1,160		1,047
Viread	303		297		862		802
Odefsey	105		—		174		—
Descovy	88		—		149		—
Other antiviral	19		15		56		53
Total antiviral products	6,841		7,702		21,150		22,321
Other products:
Letairis	215		181		593		508
Ranexa	170		161		467		419
AmBisome	91		88		262		276
Zydelig	39		36		129		92
Other	49		43		136		126
Total product sales	$	7,405	$	8,211	$	22,737	$	23,742

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2016		2015		2016		2015
McKesson Corp.	23	%	28	%	22	%	26	%
AmerisourceBergen Corp.	18	%	19	%	18	%	20	%
Cardinal Health, Inc.	16	%	14	%	16	%	15	%